Journal of Affective Disorders
Volume 78, Issue 3 , Pages 235-241 , March 2004

Assessing the effects of bupropion SR on mood dimensions of depression

  • Andrew J. Tomarken

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Vanderbilt University, Nashville, TN, USA
    • Corresponding Author InformationCorresponding author. 301 Wilson Hall, Vanderbilt University, Nashville, TN 37203, USA. Tel.: +1-615-322-4177; fax: +1-615-343-8449.
    • ,
  • Gabriel S. Dichter

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Vanderbilt University, Nashville, TN, USA
    • ,
  • Cathryn Freid

      Affiliations

    • Department of Psychology, College of Arts and Sciences, Vanderbilt University, Nashville, TN, USA
    • ,
  • Stephanie Addington

      Affiliations

    • Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA
    • ,
  • Richard C. Shelton

      Affiliations

    • Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA

Received 17 April 2002 ,Accepted 9 July 2002.

References 

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: DSM-IV; 1994;
  2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, et al  Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry. 1995;56:395–401
  3. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry. 1997;58:137–145
  4. Brown TA, Chorpita BF, Barlow DH. Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal. J. Abnorm. Psychol. 1998;107:179–192
  5. Bryk AS, Raudenbush SW. In: Hierarchical Linear Models: Applications and Data Analysis Methods. Advanced Quantitative Techniques in the Social Sciences. 1:Newbury Park: Sage Publications; 1992;p. 265
  6. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J. Abnorm. Psychol. 1991;100:316–336
  7. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 1994;11:133–141
  8. Depue RA, Luciana M, Arbisi P, Collins P, Leon A. Dopamine and the structure of personality: relation of agonist-induced dopamine activity to positive emotionality. J. Personal. Social Psychol. 1994;67:485–498
  9. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl.). 2001;155:52–57
  10. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Edition (SCID-I/NP, Version 2.0). Washington, DC: American Psychiatric Press; 1996;
  11. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch. Gen. Psychiatry. 1993;50:739–750
  12. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55
  13. Hamilton MA. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–62
  14. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology. 2002;42:181–190
  15. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Publishing; 1996;
  16. Nomikos GG, Damsma G, Wenkstem D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology. 1989;2:273–279
  17. Salamone JD. The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. J. Neurosci. Methods. 1996;64:137–149
  18. Shelton RC, Tomarken AJ. Can recovery from depression be achieved?. Psychiatr. Serv. 2001;52:1469–1478
  19. Tomarken, A.J., Shelton, R.C., Elkins, L., Anderson, T., 1997. Sleep deprivation and anti-depressant medication: unique effects on positive and negative affect. Paper presented at the American Psychological Society Meeting, Washington, DC.
  20. Trivedi MH, Rush RM, Bolden-Watson C, Houser TL, Metz A. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. J. Clin. Psychiatry. 2001;62:776–781
  21. Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. J. Abnorm. Psychol. 1995;104:15–25
  22. Watson D, Weber K, Assenheimer JS, Clark LA, Strauss ME, McCormick RA. Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales. J. Abnorm. Psychol. 1995;104:3–14
  23. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res. 1983;287:211–224
  24. Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Brain Res. 1983;287:225–236
  25. Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res. 1983;287:237–246
  26. Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav. Brain Sci. 1982;5:39–87

PII: S0165-0327(02)00306-3

doi: 10.1016/S0165-0327(02)00306-3

Journal of Affective Disorders
Volume 78, Issue 3 , Pages 235-241 , March 2004

Article Tools

* Image Usage & Resolution